Background: A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. This disease MESHD, originating in Wuhan, China, has become a global pandemic. What risk factors influence the severity of the disease MESHD is of considerable importance.Aim: This research is intended to offer a systematic review/meta-analysis for assessing how common clinical conditions and comorbidities correlate with COVID-19.Methodology: Two independent researchers undertook searches using Europe PMC, Google Scholar, and PubMed. In addition, a search engine was created for screening another 59,000 articles in COVID-19 Open Research Dataset (CORD-19). Screening was undertaken for any article related to comorbidity and their influence on the progress of the disease MESHD. Random-effects modeling was used to pool 95% confidence intervals (CIs) and odds ratios (ORs). The significance of all comorbidities and clinical conditions in relation to the severity of the disease MESHD were evaluated by employing feature extraction methods and machine-learning. Publication bias was assessed by employing funnel plots, and heterogeneity was tested in relation to I2.Results: The meta-analysis incorporated 12 studies covering 4101 confirmed COVID-19 patients from Chinese hospitals. The findings demonstrate that the most common comorbidities with the disease MESHD were hypertension MESHD hypertension HP (22.07%, OR 2.43 [95% CI: 1.71-3.45], p <0.0001), diabetes (11.34%, OR 2.27, [95% CI: 1.46-3.53], p = 0.0003), cardiovascular disease MESHD (10.76%, OR 2.89 [95% CI: 1.90-4.40], p <0.0001), and COPD (2.53%, OR 3.24 [95% CI: 1.99-4.45], p< 0.0006). No significant associations were found for disease MESHD severity with the comorbidities of kidney disease MESHD, liver disease MESHD, or cancer.The most frequently exhibited clinical symptoms were fever MESHD fever HP (74.52%, OR 1.37, 95% CI: 1.01-1.86, p = 0.04), cough MESHD cough HP (62.15%, OR 1.25, 95% CI: 0.97-1.60, p = 0.0823), myalgia MESHD myalgia HP/ fatigue MESHD fatigue HP (38.77%, OR 1.31, 95% CI: 1.11-1.55, p = 0.0018), dyspnea MESHD dyspnea HP (33.9%, OR 3.61, 95% CI: 2.57-5.06, p = <0.0001), and respiratory failure HP/ARDS (20.6%, OR 11.46, 95% CI: 3.24-40.56, p = 0.0002). Meta-analysis also revealed that neither the duration of the incubation period TRANS nor current smoking status associated with disease MESHD severity.Conclusion: Existing comorbidities, including COPD, cardiovascular disease MESHD, coronary heart disease MESHD, diabetes, and hypertension MESHD hypertension HP represent a risk of increasing the severity of the disease MESHD in COVID-19 patients.